Suppr超能文献

新冠肺炎住院患者中心脏损伤与死亡的相关性研究:中国武汉。

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.

机构信息

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.

Cardiovascular Research Institute, Wuhan University, Wuhan, China.

出版信息

JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.

Abstract

IMPORTANCE

Coronavirus disease 2019 (COVID-19) has resulted in considerable morbidity and mortality worldwide since December 2019. However, information on cardiac injury in patients affected by COVID-19 is limited.

OBJECTIVE

To explore the association between cardiac injury and mortality in patients with COVID-19.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted from January 20, 2020, to February 10, 2020, in a single center at Renmin Hospital of Wuhan University, Wuhan, China; the final date of follow-up was February 15, 2020. All consecutive inpatients with laboratory-confirmed COVID-19 were included in this study.

MAIN OUTCOMES AND MEASURES

Clinical laboratory, radiological, and treatment data were collected and analyzed. Outcomes of patients with and without cardiac injury were compared. The association between cardiac injury and mortality was analyzed.

RESULTS

A total of 416 hospitalized patients with COVID-19 were included in the final analysis; the median age was 64 years (range, 21-95 years), and 211 (50.7%) were female. Common symptoms included fever (334 patients [80.3%]), cough (144 [34.6%]), and shortness of breath (117 [28.1%]). A total of 82 patients (19.7%) had cardiac injury, and compared with patients without cardiac injury, these patients were older (median [range] age, 74 [34-95] vs 60 [21-90] years; P < .001); had more comorbidities (eg, hypertension in 49 of 82 [59.8%] vs 78 of 334 [23.4%]; P < .001); had higher leukocyte counts (median [interquartile range (IQR)], 9400 [6900-13 800] vs 5500 [4200-7400] cells/μL) and levels of C-reactive protein (median [IQR], 10.2 [6.4-17.0] vs 3.7 [1.0-7.3] mg/dL), procalcitonin (median [IQR], 0.27 [0.10-1.22] vs 0.06 [0.03-0.10] ng/mL), creatinine kinase-myocardial band (median [IQR], 3.2 [1.8-6.2] vs 0.9 [0.6-1.3] ng/mL), myohemoglobin (median [IQR], 128 [68-305] vs 39 [27-65] μg/L), high-sensitivity troponin I (median [IQR], 0.19 [0.08-1.12] vs <0.006 [<0.006-0.009] μg/L), N-terminal pro-B-type natriuretic peptide (median [IQR], 1689 [698-3327] vs 139 [51-335] pg/mL), aspartate aminotransferase (median [IQR], 40 [27-60] vs 29 [21-40] U/L), and creatinine (median [IQR], 1.15 [0.72-1.92] vs 0.64 [0.54-0.78] mg/dL); and had a higher proportion of multiple mottling and ground-glass opacity in radiographic findings (53 of 82 patients [64.6%] vs 15 of 334 patients [4.5%]). Greater proportions of patients with cardiac injury required noninvasive mechanical ventilation (38 of 82 [46.3%] vs 13 of 334 [3.9%]; P < .001) or invasive mechanical ventilation (18 of 82 [22.0%] vs 14 of 334 [4.2%]; P < .001) than those without cardiac injury. Complications were more common in patients with cardiac injury than those without cardiac injury and included acute respiratory distress syndrome (48 of 82 [58.5%] vs 49 of 334 [14.7%]; P < .001), acute kidney injury (7 of 82 [8.5%] vs 1 of 334 [0.3%]; P < .001), electrolyte disturbances (13 of 82 [15.9%] vs 17 of 334 [5.1%]; P = .003), hypoproteinemia (11 of 82 [13.4%] vs 16 of 334 [4.8%]; P = .01), and coagulation disorders (6 of 82 [7.3%] vs 6 of 334 [1.8%]; P = .02). Patients with cardiac injury had higher mortality than those without cardiac injury (42 of 82 [51.2%] vs 15 of 334 [4.5%]; P < .001). In a Cox regression model, patients with vs those without cardiac injury were at a higher risk of death, both during the time from symptom onset (hazard ratio, 4.26 [95% CI, 1.92-9.49]) and from admission to end point (hazard ratio, 3.41 [95% CI, 1.62-7.16]).

CONCLUSIONS AND RELEVANCE

Cardiac injury is a common condition among hospitalized patients with COVID-19 in Wuhan, China, and it is associated with higher risk of in-hospital mortality.

摘要

重要提示

自 2019 年 12 月以来,2019 年冠状病毒病(COVID-19)已在全球造成相当多的发病率和死亡率。然而,关于 COVID-19 患者心脏损伤的信息有限。

目的

探讨 COVID-19 患者心脏损伤与死亡率之间的关系。

设计、地点和参与者:本队列研究于 2020 年 1 月 20 日至 2 月 10 日在中国武汉的人民医院进行,最终随访日期为 2020 年 2 月 15 日。所有连续住院的 COVID-19 实验室确诊患者均纳入本研究。

主要结果和测量

收集并分析临床实验室、影像学和治疗数据。比较有和无心脏损伤患者的结局。分析心脏损伤与死亡率的关系。

结果

最终分析了 416 例住院 COVID-19 患者;中位年龄为 64 岁(范围为 21-95 岁),211 例(50.7%)为女性。常见症状包括发热(334 例[80.3%])、咳嗽(144 例[34.6%])和呼吸急促(117 例[28.1%])。82 例(19.7%)患者有心脏损伤,与无心脏损伤的患者相比,这些患者年龄更大(中位[范围]年龄,74 [34-95]岁 vs 60 [21-90]岁;P<0.001);合并症更多(例如,高血压 49 例[59.8%] vs 334 例[23.4%];P<0.001);白细胞计数更高(中位数[四分位数间距(IQR)],9400[6900-13800] vs 5500[4200-7400]细胞/μL)和 C 反应蛋白水平(中位数[IQR],10.2[6.4-17.0] vs 3.7[1.0-7.3]mg/dL),降钙素原(中位数[IQR],0.27[0.10-1.22] vs 0.06[0.03-0.10]ng/mL),肌酸激酶同工酶-肌红蛋白(中位数[IQR],3.2[1.8-6.2] vs 0.9[0.6-1.3]ng/mL),高敏肌钙蛋白 I(中位数[IQR],0.19[0.08-1.12] vs <0.006 [<0.006-0.009]μg/L),N 末端脑利钠肽前体(中位数[IQR],1689[698-3327] vs 139[51-335]pg/mL),天门冬氨酸氨基转移酶(中位数[IQR],40[27-60] vs 29[21-40]U/L)和肌酐(中位数[IQR],1.15[0.72-1.92] vs 0.64[0.54-0.78]mg/dL);影像学检查结果中多发斑片状和磨玻璃影的比例更高(53 例[64.6%] vs 15 例[4.5%])。与无心脏损伤的患者相比,有更多的心脏损伤患者需要无创性机械通气(38 例[46.3%] vs 13 例[3.9%];P<0.001)或有创性机械通气(18 例[22.0%] vs 14 例[4.2%];P<0.001)。与无心脏损伤的患者相比,有心脏损伤的患者并发症更常见,包括急性呼吸窘迫综合征(48 例[58.5%] vs 49 例[14.7%];P<0.001)、急性肾损伤(7 例[8.5%] vs 1 例[0.3%];P<0.001)、电解质紊乱(13 例[15.9%] vs 17 例[5.1%];P=0.003)、低蛋白血症(11 例[13.4%] vs 16 例[4.8%];P=0.01)和凝血障碍(6 例[7.3%] vs 6 例[1.8%];P=0.02)。与无心脏损伤的患者相比,有心脏损伤的患者死亡率更高(42 例[51.2%] vs 15 例[4.5%];P<0.001)。在 Cox 回归模型中,与无心脏损伤的患者相比,有心脏损伤的患者死亡风险更高,无论是从症状出现(风险比,4.26[95%置信区间,1.92-9.49])还是从入院到终点(风险比,3.41[95%置信区间,1.62-7.16])。

结论和相关性

心脏损伤是中国武汉住院 COVID-19 患者的常见情况,与住院死亡率升高相关。

相似文献

1
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.
JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.
3
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).
JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.
6
Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study.
Chin Med J (Engl). 2020 Jun 5;133(11):1261-1267. doi: 10.1097/CM9.0000000000000824.
7
Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.
JAMA Netw Open. 2020 Jun 1;3(6):e2010895. doi: 10.1001/jamanetworkopen.2020.10895.
9
Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital Experience and Policy Implications.
Am J Nephrol. 2020;51(10):786-796. doi: 10.1159/000511160. Epub 2020 Oct 2.
10
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.

引用本文的文献

2
Consensus based recommendations for the management of post-COVID long-term sequelae (Long COVID): a regional perspective.
Front Med (Lausanne). 2025 Aug 6;12:1453167. doi: 10.3389/fmed.2025.1453167. eCollection 2025.
4
What Long COVID investigators can learn from four decades of ME/CFS research.
Brain Behav Immun Integr. 2023 Dec;4. doi: 10.1016/j.bbii.2023.100022. Epub 2023 Sep 7.
5
Plasma Soluble ST2 as a Prognostic Biomarker for Cardiovascular Events and Mortality in COVID-19 Patients.
J Cardiovasc Dev Dis. 2025 Jul 17;12(7):273. doi: 10.3390/jcdd12070273.
7
COVID-19 and Myocarditis: Trends, Clinical Characteristics, and Future Directions.
J Clin Med. 2025 Jun 27;14(13):4560. doi: 10.3390/jcm14134560.
9
Development and validation of COVID-19 with myocardial injury based on 3 methods.
Medicine (Baltimore). 2025 Jun 27;104(26):e43142. doi: 10.1097/MD.0000000000043142.
10
Two-year follow-up of patients with myocardial injury during acute COVID-19: insights from the CARDIO COVID 20-21 registry.
Front Cardiovasc Med. 2025 Jun 11;12:1584732. doi: 10.3389/fcvm.2025.1584732. eCollection 2025.

本文引用的文献

2
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
3
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
Science. 2020 Mar 13;367(6483):1260-1263. doi: 10.1126/science.abb2507. Epub 2020 Feb 19.
5
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
6
The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection.
Influenza Other Respir Viruses. 2017 Sep;11(5):372-393. doi: 10.1111/irv.12470.
7
Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus.
Ann Saudi Med. 2016 Jan-Feb;36(1):78-80. doi: 10.5144/0256-4947.2016.78.
8
Acute pneumonia and the cardiovascular system.
Lancet. 2013 Feb 9;381(9865):496-505. doi: 10.1016/S0140-6736(12)61266-5. Epub 2013 Jan 16.
9
Acute respiratory distress syndrome: the Berlin Definition.
JAMA. 2012 Jun 20;307(23):2526-33. doi: 10.1001/jama.2012.5669.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验